Literature DB >> 464573

Role of vancomycin as a component of oral nonabsorbable antibiotics for microbial suppression in leukemic patients.

J F Bender, S C Schimpff, V M Young, C L Fortner, M D Brouillet, L J Love, P H Wiernik.   

Abstract

A total of 38 adult patients with acute leukemia who were undergoing remission induction chemotherapy in regular patient rooms were randomly allocated to one of two oral nonabsorbable antibiotic regimens for infection prophylaxis (gentamicin, vancomycin, and nystatin [GVN] or gentamicin and nystatin [GN]) to evaluate whether vancomycin was a necessary component. The patient population in both groups were comparable. Tolerance to GVN was less than GN but compliance was approximately equal (>85% in both groups). Patients receiving vancomycin demonstrated greater overall alimentary tract microbial suppression; however, acquisition of potential pathogens was approximately equal in both groups. The incidence of bacteremia, as well as the overall incidence of infection as related to the number of days at various granulocyte levels, was also approximately equal in both groups. Group D Streptococcus species were poorly suppressed by GN compared with GVN, although no patient developed an infection with these organisms. Colonization by newly acquired gram-negative bacilli was significantly less in the GN group (GN, 3 colonizations; GVN, 13 colonizations; P < 0.01). It is concluded that vancomycin may be safely eliminated from the GVN regimen provided microbiological data is monitored to detect resistant organisms.

Entities:  

Mesh:

Substances:

Year:  1979        PMID: 464573      PMCID: PMC352683          DOI: 10.1128/AAC.15.3.455

Source DB:  PubMed          Journal:  Antimicrob Agents Chemother        ISSN: 0066-4804            Impact factor:   5.191


  17 in total

1.  Therapy of infection in patients with granulocytopenia.

Authors:  S C Schimpff
Journal:  Med Clin North Am       Date:  1977-09       Impact factor: 5.456

2.  Gastrointestinal "sterilization" in the treatment of patients with acute leukemia.

Authors:  H D Preisler; I M Goldstein; E S Henderson
Journal:  Cancer       Date:  1970-11       Impact factor: 6.860

3.  Protected environments and prophylactic antibiotics. A prospective controlled study of their utility in the therapy of acute leukemia.

Authors:  A S Levine; S E Siegel; A D Schreiber; J Hauser; H Preisler; I M Goldstein; F Seidler; R Simon; S Perry; J E Bennett; E S Henderson
Journal:  N Engl J Med       Date:  1973-03-08       Impact factor: 91.245

4.  Antibiotic susceptibility testing by a standardized single disk method.

Authors:  A W Bauer; W M Kirby; J C Sherris; M Turck
Journal:  Am J Clin Pathol       Date:  1966-04       Impact factor: 2.493

5.  A controlled study of isolation and endogenous microbial suppression in acute myelocytic leukemia patients.

Authors:  J W Yates; J F Holland
Journal:  Cancer       Date:  1973-12       Impact factor: 6.860

6.  Prophylaxis against septicaemia in acute leukaemia: the use of oral framycetin.

Authors:  M J Keating; D G Penington
Journal:  Med J Aust       Date:  1973-08-04       Impact factor: 7.738

7.  Selective elimination of Enterobacteriaceae species from the digestive tract in mice and monkeys.

Authors:  D van der Waaij; J M Berghuis-de Vries
Journal:  J Hyg (Lond)       Date:  1974-04

Review 8.  Hematologic malignancies and other marrow failure states: progress in the management of complicating infections.

Authors:  A S Levine; S C Schimpff; R G Graw; R C Young
Journal:  Semin Hematol       Date:  1974-04       Impact factor: 3.851

9.  Infection in acute leukemia patients receiving oral nonabsorable antibiotics.

Authors:  D M Hahn; S C Schimpff; C L Fortner; A C Smyth; V M Young; P H Wiernik
Journal:  Antimicrob Agents Chemother       Date:  1978-06       Impact factor: 5.191

10.  Oral non-absorbed antibiotics prevent infection in acute non-lymphoblastic leukaemia.

Authors:  R A Storring; B Jameson; T J McElwain; E Wiltshaw
Journal:  Lancet       Date:  1977-10-22       Impact factor: 79.321

View more
  6 in total

1.  Preventing infection in neutropenic cancer patients.

Authors:  S M Beutler; N M Barth; A S Bayer
Journal:  West J Med       Date:  1983-05

2.  Prophylactic non-absorbable antibiotics in leukaemic patients.

Authors:  K King
Journal:  J Hyg (Lond)       Date:  1980-08

Review 3.  Selective antimicrobial modulation of the intestinal flora. Prophylaxis against infection in neutropenic patients.

Authors:  H F Guiot; R van Furth
Journal:  Infection       Date:  1984 Jan-Feb       Impact factor: 3.553

Review 4.  Antibiotic prophylaxis for bacterial infections in afebrile neutropenic patients following chemotherapy.

Authors:  Anat Gafter-Gvili; Abigail Fraser; Mical Paul; Liat Vidal; Theresa A Lawrie; Marianne D van de Wetering; Leontien C M Kremer; Leonard Leibovici
Journal:  Cochrane Database Syst Rev       Date:  2012-01-18

5.  Functional imaging of the interaction between gut microbiota and the human host: A proof-of-concept clinical study evaluating novel use for 18F-FDG PET-CT.

Authors:  Ben Boursi; Thomas J Werner; Saeid Gholami; Sina Houshmand; Ronac Mamtani; James D Lewis; Gary D Wu; Abass Alavi; Yu-Xiao Yang
Journal:  PLoS One       Date:  2018-02-15       Impact factor: 3.240

Review 6.  Host impairments in patients with neoplastic diseases.

Authors:  J Peter Donnelly; Nicole M A Blijlevens; Walter J F M van der Velden
Journal:  Cancer Treat Res       Date:  2014
  6 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.